Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
Executive Summary
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.
You may also be interested in...
US FDA CDER, CBER Staff Say Pandemic Had Negative Effect On Hiring, Retention
Human resource managers also worried that since universal teleworking was valued by employees, a return to pre-pandemic conditions could cause a mass exodus.
Generic Labeling Problems Targeted In US FDA Budget Request
Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.
US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.